Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment

By A. Garrido-Castro, N. Lin, K. Polyak. Cancer Discovery, 2019

1,080 citations recorded by the source corpus.

SUMMARY Triple-negative breast cancer (TNBC) remains the most challenging breast cancer subtype to treat. To date, therapies directed to specific molecular targets have rarely achieved clinically meaningful improvements in outcomes of patients with TNBC, and chemotherapy remains the standard-of-care. Here we seek to review the most recent efforts to classify TNBC based on comprehensive profiling of tumors for cellular composition and molecular features. Technological advances allow for tumor characterization at ever increasing depth, generating data that, if integrated with clinical-pathologic features, may help improve risk stratification of patients, guide treatment decisions and surveillance, and help identify new targets for drug development.

Subfields: Cancer Research, Oncology

View Paper: https://www.semanticscholar.org/paper/9ac432cda71c604d6000f97083bc71c000bd98ba

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Yongheng Chen
2. S. Leonov
3. Huajun Zhang
4. Lin Chen
5. Na Liu
6. Yun R Li
7. Yulia Merkher

Citations in the corpus

• Recent advances in therapeutic strategies for triple-negative breast cancer (2022, background): “Despite the promising efficacy of PARPi in TNBC, partial PARP-insensitive BRCA mutations of TNBC and acquired therapeutic resistance have been problematic in long-term studies [2].”